Review Article

Novel Therapeutic Strategies for Ischemic Stroke: Recent Insights into Autophagy

Xiaocheng Lu,1 Jian Zhang,1 Yu Ding,1,2 Jiang Wu,1 and Gang Chen1

1Department of Neurosurgery, Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, China
2Department of Neurosurgery, The Affiliated Suqian Hospital of Xuzhou Medical University, No.138, Huanghe South Road, Suqian, 223800 Jiangsu, China

Correspondence should be addressed to Jiang Wu; szjiangwu@163.com and Gang Chen; nju_neurosurgery@163.com

Received 9 December 2021; Revised 24 April 2022; Accepted 11 May 2022; Published 8 June 2022

Academic Editor: Kamil Duris

Copyright © 2022 Xiaocheng Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stroke is one of the leading causes of death and disability worldwide. Autophagy is a conserved cellular catabolic pathway that maintains cellular homeostasis by removal of damaged proteins and organelles, which is critical for the maintenance of energy and function homeostasis of cells. Accumulating evidence demonstrates that autophagy plays important roles in pathophysiological mechanisms under ischemic stroke. Previous investigations show that autophagy serves as a "double-edged sword" in ischemic stroke as it can either promote the survival of neuronal cells or induce cell death in special conditions. Following ischemic stroke, autophagy is activated or inhibited in several cell types in brain, including neurons, astrocytes, and microglia, as well as microvascular endothelial cells, which involves in inflammatory activation, modulation of microglial phenotypes, and blood-brain barrier permeability. However, the exact mechanisms of underlying the role of autophagy in ischemic stroke are not fully understood. This review focuses on the recent advances regarding potential molecular mechanisms of autophagy in different cell types. The focus is also on discussing the "double-edged sword" effect of autophagy in ischemic stroke and its possible underlying mechanisms. In addition, potential therapeutic strategies for ischemic stroke targeting autophagy are also reviewed.

1. Introduction

Stroke, also known as cerebrovascular accident, is one of the leading causes of death worldwide, and survivors frequently experience long-term cognitive and functional limitations. Stroke can be classified as two main types: hemorrhagic stroke and ischemic stroke, of which, the later one is the common type of stroke, due to insufficient blood supply to the brain. To date, intravenous recombinant tissue plasminogen activator (rtPA) is the only Food and Drug Administration (FDA)-approved treatment strategy for acute ischemic stroke [1, 2]. Intravenous thrombolysis has been proven to be a relatively safe and efficient treatment; however, there are still some limitations, such as the therapeutic window which is 3-4.5 h following symptom onset and it may cause intracerebral hemorrhage [2, 3]. Thus, cutting-edge investigations on novel treatment strategies for ischemic stroke are urgently needed.

Autophagy, first defined by De Duve, is an evolutionarily conserved process for degrading and recycling of unnecessary or dysfunctional cellular components and proteins [4]. It is activated in response to stress conditions, such as nutrient limitation and oxidative stress. Autophagy has been shown to play a variety of pathophysiological roles in many disease, including neurodegenerative disease, liver disease, aging, and cardiovascular disease [5–8]. Moreover, autophagy is extensively observed in ischemic brain tissues, and the roles of autophagy in the ischemic stroke have been widely studied [9]. However, to date, the exact roles of autophagy in ischemic stroke are still controversial. Therefore, this review aims to focus on the function of autophagy in ischemic stroke, including in modulation of microglial phenotypes, activation of astrocytes, neuronal cells death, and blood-brain barrier (BBB) permeability. We will also discuss the possibility of treatments targeting autophagy as novel therapeutic strategies for ischemic stroke in the future.
2. Autophagy: An Overview

Autophagy is a cellular degradation machinery which is evolutionarily conserved from yeast to mammals and plays an important role in differentiation, development, and cellular homeostasis [10, 11]. It is activated by nutrient limitation or metabolic stress to degrade misfolded proteins or damaged organelles into metabolic elements. Dysregulation of autophagy is observed in a wide range of pathological conditions, including Alzheimer’s disease, breast cancer, kidney disease, and inflammatory bowel diseases. [12–16] The known classes of autophagy in mammalian cells are macroautophagy, microautophagy, and chaperone-mediated autophagy.

2.1. Macroautophagy. Macroautophagy, initially studied in yeast and conserved across evolution, is characterized by sequestration of cytoplasmic material, such as organelles, protein aggregates, and lipid droplets, in a double-membrane-bound vacuole called the autophagosomes in a selective way. Subsequently, the autophagosomes deliver cargo to the lysosome for final degradation [17, 18]. For selective macroautophagy, autophagy adaptors (such as P62, NBR1, NDP52, and OPTN) specifically target cellular cargo to the autophagosomes for autophagy in an ubiquitin-dependent (Ub-dependent) or Ub-independent pathway [19–21]. Several protein complexes have been reported to be essential for the formation of autophagosome, including unc-51 like autophagy activating kinase 1 (ULK1) complex, microtubule-associated protein 1 light chain 3 (LC3)-phosphatidylethanolamine (PE) conjugation, and ATG5-ATG12 complex, as well as a complex of class III phosphatidylinositol 3-kinase (PI3K) composed of vacuolar protein sorting 34 (VPS34), VPS15, and Beclin 1 (Atg6 in yeast), which can be blocked by the PtdIns3K inhibitors 3-MA. Macroautophagy is the most common and best characterized form of autophagy and will be referred to as autophagy thereafter and mainly discussed in the present review.

2.2. Microautophagy. Microautophagy is a nonselective lysosomal degradative process in mammalian cells, which has been mainly investigated in yeast but is not well defined in mammalian cells [22]. Microautophagy can be induced by nitrogen starvation or rapamycin and plays a crucial role in the maintenance of organellar size, membrane homeostasis, and cell survival under nitrogen restriction. It has been shown that microautophagy is involved in direct engulfment of cytoplasmic proteins or organelles such as long-lived proteins and membrane proteins into the lysosome via invagination [22, 23], which was regulated by a dynamin-related GTPase Vps1p [24].

2.3. Chaperone-Mediated Autophagy. Chaperone-mediated autophagy (CMA) is an extremely selective type of autophagy, recognizing the substrate proteins containing specific pentapeptide motif KFERQ via a chaperon protein, heat shock protein 70 (HSP70). Upon recognition, the substrate/chaperone complex is translocated across the lysosome membrane, engulfed, and degraded by lysosomes dependent on the lysosomal membrane protein 2A (LAMP2A). Recently, accumulating studies showed important roles of CMA in Parkinson disease, immunosuppression, and the development of hepatocellular carcinoma [25–27].

3. Process of Autophagy

3.1. Initiation and Nucleation of Autophagy. Under various conditions of stress like starvation, hypoxia, and oxidative stress, autophagy is initiated by activation of the ULK1 complex (consisting of ULK1, autophagy-related protein 13 (ATG13), RB1-inducible coiled-coil protein 1 (FIP200), and ATG101), which is controlled via phosphorylation by the energy sensor 5-AMP-activated protein kinase (AMPK) and the metabolic integrator mecha
testicin complex 1 (mTORC1) [28]. The nucleation is triggered via the activation of class III PI3K complex, which consists of VPS 34 (also known as PIK3 C3), Beclin 1, autophagy-related protein 14-like protein (ATG14L), activating molecule in Beclin 1-regulated autophagy protein 1 (AMBRA1), and general vesicular transport factor (p115), which in turn increases the local concentration of phosphatidylinositol-3-phosphate (PI3P) [29, 30].

3.2. Elongation. PI3P produced by the PI3K complex recruits the PI3P effector proteins WD repeat domain phosphoinositide-interacting protein (WIPI2) and zinc-finger FYVE domain-containing protein 1 (DFCP1) to the omegasome. Next, two ubiquitin-like systems activated by WIPI2 and DFCP1 elongate the autophagosome. The first is the ATG12 system, in which ATG5 is covalently conjugated to ATG12 through the actions of atg7 and atg10 and then associates with ATG16L1 to form the ATG12–ATG5–ATG16L complex [31, 32]. The second system results in the binding of PE and ATG8, including microtubule-associated protein 1 light chain 3 (LC3) and y-a

3.3. Fusion and Degradation. To be degraded, the autophagosome next fuses with the lysosome and matures into an autolysosome [38], which is regulated by soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins and homotypic vacuole fusion and prote

4. Autophagy in Ischemic Stroke

4.1. Autophagy in Neurons after Ischemic Stroke. Although accumulating studies indicated that autophagy played a critical role in starvation-induced protein turnover and damaged...
organelles elimination, the exact role of autophagy in neurons is complex. Under normal conditions, autophagy is maintained at relatively low levels in neurons. Neuron is the most sensitive cells upon ischemia, and several studies have reported the enhanced neuronal autophagy in response to cerebral ischemic injury [42–44] (Figure 1). Using green fluorescent protein (GFP)-fused LC3 transgenic mice, Xie et al. demonstrated that GFP-LC3 fluorescent signals were detected above the ischemic hemisphere (especially in the peri-ischemic area) at 1, 3, and 6 d after transient middle cerebral artery occlusion (tMCAO), with a peak at 1 d. A recent study observed that selective neuronal deletion of the Atg7 (autophagy-related 7) gene prevented hypoxia-ischemia (HI)-induced autophagy, decreased 42% of tissue loss compared to wild-type mice, and reduced neuronal cell death [45]. Astrocyte-derived proinflammatory cytokine interleukin (IL)-17A has been shown to aggravate neuronal ischemic injuries and enhance autophagy oxygen glucose deprivation/reperfusion (OGD/R)-treated neurons. In addition, intracerebroventricular injection of IL-17A neutralizing mAb improved functional recovery in ischemic mice via inhibition of neuronal autophagy through Src-PP2B-mTOR pathway [46]. Zeng et al. demonstrated that knockdown of regulated in development and DNA damage responses 1 (REDD1), a conserved stress response gene [47], reversed the excessive activation of autophagy in neurons, reduced neuronal oxidative stress, and attenuated neuronal cell death upon OGD/R. Moreover, the protective effect of REDD1 suppression could be abolished by blocking the mTOR pathway via rapamycin treatment [48]. The following studies also confirmed the detrimental effects of neuronal autophagy in ischemic stroke [49–55].

Indeed, autophagy has been identified as a double-edged sword in neurons after ischemic stroke [56]. There were also a

![Figure 1: Manipulation of autophagy in neurons after ischemic stroke.](image-url)
large number of studies that observed opposite effect of neuronal autophagy in ischemic stroke [57–60]. Our previous study showed that receptor for activated protein kinase C 1 (RACK1), an integral component of ribosomes, was decreased in neurons within penumbra tissue after MCAO. Phosphorylation of RACK1 at T50 reduced infarct size, neuronal death, neuronal tissue loss, and neurobehavioral dysfunction, through promoting Beclin 1 binding in axons and autophagy induction after ischemia [61]. In line with our results, previous studies demonstrated that inhibition of autophagy by 3-MA or Atg7 knockdown enhanced the I-R-induced release of cytochrome c and aggravated ischemia-induced neuronal cell death [9, 62]. In addition, treatment with rapamycin, an mTOR inhibitor, increased autophagy and reduced neuronal death and brain injury in neonatal HI [63, 64]. These results have been confirmed in the following studies in MCAO models [65–68]. A recent study indicated that sphingosine kinase 2 (SPK2) overexpression protected cortical neurons against OGD injury via enhancement of autophagy flux. Moreover, the mechanism underlying autophagy activation induced by SPK2 was that SPK2 interacts with Bcl-2 via its BH3 domain, thereby dissociating it from Beclin 1 complex and activating autophagy. [69] It was also reported that expression of the endogenous NPC1L1 (Niemann–Pick disease type C1-like 1) increased mainly in neurons after MCAO. Treated with NPC1L1 inhibitor ezetimibe (Eze) attenuated neuronal apoptosis and improved long-term neurological recovery in the rat model of MCAO, specifically via activation of the AMPK/ULK1/autophagy pathway [70]. The neuroprotective roles of neuronal autophagy in ischemic stroke have also been confirmed in several studies [71–74].

4.2. Autophagy in Microglia after Ischemic Stroke. Microglia are the major immune cells in brain involved in the postischemic inflammation [75]. Following ischemia, microglial cells were activated with different phenotypes with distinct functions, mainly including M1 and M2 phenotypes [76–80]. The M1 microglia secretes proinflammatory factors, such as interleukin (IL)-6, IL-18, and tumor necrosis factor-alpha (TNF)-α, further contributing to severe ischemic injury [81]. Conversely, M2 microglia releases anti-inflammatory mediators, which are responsible for scavenging of debris and secreting trophic factors for brain repair [82]. Recently, there has been increasing evidence that autophagy, especially microglia autophagy, played an important role in the neuroinflammatory response after ischemic stroke (Figure 2).

HI was reported to induce M1 polarization of microglia/macrophages, which contributed to the neuronal death in
neonatal mice. The authors also found that excessive CatB-mediated autophagy in microglia cells played an essential role in the neurotoxic polarization of microglia/macrophages following HI injury [83]. Using a permanent middle cerebral artery occlusion (pMCAO) model in mice, Yang et al. observed that autophagy was induced in microglia cells, accompanied with increased inflammatory response. Treatment with 3-MA decreased microglia autophagy and inflammatory response, subsequently decreased infarct size and edema formation, and improved functional recovery [84]. A recent study indicated that baicalein, a biologically active ingredient extracted from the root of Scutellaria baicalensis Georgi, reduced neurobehavioral deficits and decreased brain infarct volume via inhibiting M1 transformation of microglia/macrophage and neuroinflammation. They observed that NF-κB and MAPK signaling pathways were involved in the regulation of microglia/macrophages M1/M2 transformation. Moreover, baicalein also inhibited autophagy via the PI3K/Akt/mTOR signaling pathway [85]. Interestingly, He et al. demonstrated that ischemic stroke activated autophagy signaling in penumbra and reduced CX3CL1 expression on autophagic neurons, finally promoting microglial inflammation. Autophagy inhibitor 3-MA was shown to reverse the microglial inflammatory injury induced by ischemic stroke, whereas treatment with the autophagy inducer Tat-Beclin 1 aggravated the microglial inflammation and cerebral edema [86]. Several recent researches also inhibition of microglia autophagy might be a potential therapeutic strategy for ischemic stroke treatment [87–89].

Although accumulating studies showed a detrimental role of microglia autophagy in ischemic stroke, Han et al. showed that overexpression of microglia-specific PGC-1α significantly decreased neurologic deficits after ischemic injury, with reduced NLRP3 activation and proinflammatory cytokine production via activation autophagy [90]. Moreover, a recent study demonstrated that activation of autophagy in microglial cells was time dependent and inhibition of microglia autophagy promoted neuroinflammation. They observed that the autophagic flux was induced at early phase of OGD/R (12h, 24h, and 48h after OGD/R) whereas inhibited at the late phase of OGD/R (72h after OGD/R). Xia et al. also demonstrated that inhibition of autophagic flux induced M1 microglial phenotype of microglial cells with increased tumor necrosis factor-alpha (TNF-α), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2). In addition, autophagy participated in the alternation of microglial phenotype via modulating NF-κB pathway and activity of CREB [91]. The neuroprotective roles of microglia autophagy in ischemic stroke have also been indicated in other studies [92, 93].

4.3. Autophagy in Astrocytes after Ischemic Stroke. Astrocytes are the most abundant cell type within the central nervous system, and they play essential roles in maintaining normal brain function, including structural support, neuronal metabolism, maintenance of the extracellular environment, and neurotransmitter synthesis [94–96]. Following ischemic stroke, astrocytes perform multiple functions both detrimental and beneficial. Astrocytic inflammatory response aggravates the ischemic lesion, and the glial scar obstructs axonal regeneration during the late phase after stroke [97–99]. However, astrocytes also provide benefit for angiogenesis, synaptogenesis, and axonal remodeling [100–102].

Autophagy in astrocytes was induced by cerebral ischemia as evidenced by the increased expression of autophagy and autolysosome-related proteins, including microtubule-associated protein 1 light chain 3 (LC3-II), Beclin 1, lysosome-associated membrane protein 2 (LAMP2), and lysosomal cathepsin B. Furthermore, inhibition of autophagy by 3-MA attenuated OGD-induced death of astrocytes and increased GFAP-positive cells in the ischemic cortex 12 h following pMCAO. [103] Similarly, Zhou et al. showed that autophagy was activated in ischemic astrocytes and pharmacological or genetic inhibition of autophagy reversed OGD-induced release of cathepsin B and L from the lysosome to the cytoplasm and activation of caspase-3 in the astrocytes, decreased OGD-induced increase in lysosomal membrane permeability, and subsequently reduced OGD-induced astrocyte cell death and infarction volume in rats [104]. Receptor-interacting protein 1 kinase (RIP1K) is a crucial mediator of necroptosis after ischemic stroke. Ni et al. demonstrated that OGD or pMCAO condition increased the expression of RIP1K (receptor-interacting protein 1 kinase), RIP3K, and RIP1K–RIP3K complex. They further found that pharmacological or genetic inhibition of RIP3K attenuated astrocytic necrotic cell death in the ischemic cortex, reduced infarct volume, and improved neurological deficits in the MCAO model. In addition, a combination of Nec-1 (pharmacological inhibitor of RIP3K) and an inhibitor of autophagy produced an enhancement protective effect on astrocytic cell death after ischemic stroke, suggesting that activation of the autophagic-lysosomal pathway was involved in the RIP1K-mediated ischemic astrocytic necroptosis [105]. Using a circRNA microarray, Han et al. found that circular RNA Hectd1 (circHectd1) levels were significantly increased in both ischemic brain tissues in transient MCAO mouse stroke models and in plasma samples from acute ischemic stroke patients. CircHectd1 acts as an endogenous RNA sponge and binds miR-142 to promote astrocytic autophagy via the downstream target TIPARP (TCDD inducible poly [ADP-ribose] polymerase), resulting in astrocyte activation in stroke. Knockdown of circHectd1 expression significantly attenuated astrocytic autophagy, decreased infarct areas, attenuated neuronal deficits, and ameliorated astrocyte activation in tMCAO mice [106]. A recent study also confirmed the detrimental effects of astrocyte autophagy in ischemic stroke [107].

However, several studies observed the contrary results [108–110] (Figure 3). Back et al. demonstrated that activation astrocytic GPR30 (G protein-coupled receptor 30) restored autophagy in glutamate-induced astrocyte via p38 mitogen-activated protein kinase (MAPK) signaling pathway, inhibited reactive astrogliosis, and decreased inflammatory cytokine release, finally reducing the neurological deficit scores and the infarct volume after MCAO [111]. Interestingly, a recent study demonstrated that upregulation of autophagy flux of astrocytes decreased neuronal apoptosis
after exposed to OGD/R. Moreover, induction of astrocyte autophagy by AAV-GFAP-ATG7 in vivo improved neurological recovery in MCAO model in mice, suggesting that astrocytic autophagy might contribute to endogenous neuroprotective and neurological recovery after stroke [67].

4.4. Autophagy in Oligodendrocytes after Ischemic Stroke. Oligodendrocytes are abundant in both gray and white matter of the brain and are the only cells able to form the myelin sheath in the CNS [111, 112]. However, most of oligodendrocytes are dead after ischemic stroke, which are associated with neurological defect [113, 114]. In response to ischemic injury, oligodendrocyte progenitor cells, derived from NPCs (neural progenitor cells) in the SVZ (subventricular zone), proliferate and differentiate into oligodendrocytes to form new myelin sheaths [115, 116]. A recent study demonstrated that autophagy played a critical role in the oligodendrocyte differentiation, survival, and proper myelination. Mice with conditional OPC/OL-specific deletion of Atg5 beginning on postnatal day 5 developed a rapid tremor and died around postnatal day 12, with apoptotic death of OPCs and reduction in differentiation and myelinated axons. In addition, induction of autophagy in OPCs promoted myelination of DRG neurons in cocultures, which was blocked with autophagy inhibition [117]. Current evidence indicated that oligodendrocyte autophagy played an important role in neurodegenerative disease and spinal cord injury [118–121]. However, studies involved in autophagy of oligodendrocytes after ischemic stroke were limited.

4.5. Autophagy in Brain Microvascular Endothelial Cells and BBB Permeability after Ischemic Stroke. Blood-brain barrier (BBB), composed of brain microvascular endothelial cells (BMVECs), perivascular astrocytes, neurons, and pericytes, regulates substance influx and efflux to maintain a normal physiology of brain. Among them, BMVECs, connected by tight junctions, play a critical role in the maintaining BBB integrity [122, 123]. It has been reported that the impairment of BBB integrity is a common pathological feature after ischemic stroke, which subsequently aggravates brain edema and neuronal injury [124, 125]. Accumulating studies focused on the role of autophagy in BBB dysfunction in ischemic stroke (Figure 4). FAK-phosphorylation-dependent activation of autophagy served as an endogenic protective response to endothelial injury in vitro induced by methylglyoxal (MGO), a reactive dicarbonyl which could exacerbate ischemia-induced BMEC injury. The beneficial effect of autophagy was also observed in the MCAO model [126]. We recently observed that enhancement of autophagy by rapamycin attenuated BMVEC apoptosis after OGD/R,
whereas which was increased via autophagy inhibition by 3-methyladenine (3-MA). Moreover, autophagy induced by rapamycin and lithium carbonate also attenuated the decrease expression of ZO-1, a kind of tight junction protein, and promoted the distribution of ZO-1 on cell membranes, indicating a beneficial effect of BMVEC autophagy on BBB integrity [127]. This was also supported by Urbanek et al., who showed that treatment with rapamycin increased the viability of human umbilical vein endothelial cells (HUVECs) after OGD, whereas knockdown of Beclin 1 by siRNAs attenuated the autophagy and reduced cell viability of HUVECs [128]. In addition, Yu et al. showed that Netrin-1, an axonal guidance molecule, enhanced autophagy activity via PI3K pathway depending on UNC5H2 receptor and attenuated BBB impairment induced by ischemic stroke by promoting tight junction function and endothelial survival [129]. Moreover, recent studies also suggested that endothelial autophagy might contribute to blood-brain barrier protection after ischemic stroke [130, 131].

On the other hand, increasing evidence suggested a detrimental role of endothelial autophagy in BBB dysfunction in ischemia. After focal ischemia in the barrel cortex, increased autophagy-like cell death (including in BMVECs and neurons) and BBB impairment were observed in NF-κB p50 knockout mice, which could be reversed by autophagic inhibition [132]. Zhang et al. demonstrated that enhanced autophagy in rats with hyperglycemia contributed to the autophagy-lysosome-mediated degradation of ZO-1 and was, at least partially, responsible for the BBB dysfunction after MCAO [133]. Similar results were observed in a recent study [134]; using in vitro OGD model in mouse BMVECs, Liu et al. showed that inhibition of autophagy or the fusion of autophagosome with lysosome blocked OGD-induced claudin-5 degradation, subsequently attenuated endothelial barrier disruption [135]. Taken together, these results showed a detrimental role of endothelial autophagy in BBB dysfunction after ischemic stroke [136].

5. Autophagy: A Double-Edged Sword in Ischemic Stroke

Emerging evidence suggests that autophagy serves as a double-edged sword in several human diseases, such as neurodegenerative diseases [137], cancer [138], and infectious diseases [139]. Likewise, as all the evidence above shows, either the absence of autophagy or excessive autophagy...
may be detrimental to the outcomes of cerebral ischemia. However, currently there is no unified theory of whether autophagy plays a beneficial or detrimental role in ischemic stroke. Based on studies over past few years, there were two potential factors that determine the role of autophagy in ischemic stroke, the levels of autophagy, and the time of autophagy.

Kang et al. demonstrates that levels of autophagy are critical for the fate of cells, moderate or adaptive autophagy can promote survival, whereas excessive (maladaptive) levels of autophagy promote cell death [140]. This speculation may be supported by an in vitro OGD model, the results of which show the dual role of 3-MA at different time points of reoxygenation [141]. Autophagy inhibition by 3-MA at 24 hours prior to reperfusion triggers a higher neuronal death rates, whereas at 48 and 72 hours after reperfusion, 3-MA treatment significantly protected neurons from death. It is possible that transient ODG induces adaptive autophagy that eliminates damaged organelles to rescue neurons, while prolonged OGD triggers excessive autophagy leading to neurons death and switching its role from protection to deterioration.

In addition, the time at which autophagy induced is another key variable in the balance between protective or detrimental autophagy. It has been shown that in the treatment with rapamycin or 3-MA 20 minutes before hypoxia-ischemia, rapamycin reduces necrotic cell death and decreases brain injury via autophagy induction, while 3-MA inhibits autophagy and promotes neuronal death [63, 64]. Conversely, Puyal et al. indicated that postischemic intracerebroventricular injections of 3-MA significantly reduced the lesion volume (by 46%) [44]. This was supported by a study in which administration of 3-MA suppressed autophagy induced by preconditioning and attenuated the neuroprotection of preconditioning against cerebral ischemia. In contrast, pretreatment with rapamycin mimicked the neuroprotective effect of ischemic preconditioning [142]. Gao et al. reported that induction of autophagy by rapamycin attenuate the neuroprotective effects of ischemic postconditioning in the MCAO model [143], whereas blocking the AKT-GSK3β signaling pathway prior to ischemic postconditioning suppressed the autophagy and neuroprotection of ischemic postconditioning [144]. Qi et al. also found that the involvement of Akt mediated Bcl-2 phosphorylation and thereby Bcl-2/Bclin1 complex disruption played a crucial role in triggering autophagy and were essential for the neuroprotective effects of ischemic postconditioning [145]. Based on these findings, manipulation of autophagy at different time point after ischemic stroke may also determine its role, suggesting that adaptive autophagy induced at early stage may provide a prosurvival effect but prolonged and excessive autophagy causes nerve injury at late stage. Moreover, manipulation of autophagy in specific type of cells by cell-specific deletion of autophagy-related genes might be a reason for discovering contradictory results, because interfering with autophagy in single cell type might not prove it decisively contributes to beneficial or harmful results after ischemic stroke [45, 146]. Finally, the controversial effects of autophagy may also be due to the different model types, different types of selective autophagy, different means of intervention, or even sex-specific differences in experimental animal [147–149].

6. Potential Therapeutic Strategies for Ischemic Stroke Targeting Autophagy Manipulation

According to the aforementioned studies, therapeutic strategies targeting autophagy modulation may be a possible approach in the management of IS. To date, multiple potential therapeutic agents have been explored [150–154]. These agents modulate different processes of autophagy including (A) inducing adaptive autophagy and (B) inhibiting excessive autophagy following IS. A variety of compounds have been shown to induce adaptive autophagy. Among these compounds, rapamycin is widely examined in the management of IS via inhibition of mTOR. Recent investigations indicated that administration of rapamycin in rodents undergoing MCAO could diminish infarct volume, reduce neuronal injury, and improve neurological recovery [68, 155, 156]. Rapamycin also has been reported to reduce endothelial cell death and improve BBB permeability in an MCAO model [127, 157]. A recent systematic review involving 17 publications demonstrated that rapamycin significantly reduced infarct volume by 21.6% and improved in neurobehavioral scores by 30.5%. Interestingly, lower doses of rapamycin showed greater efficacy at reducing infarct volume than higher doses, which is potentially due to an optimal level of autophagy activation with low dose of rapamycin [156, 158, 159]. Resveratrol, a common dietary polyphenol, has been shown to extend the clinical therapeutic window of r-tPA for stroke patients [160]. He et al. revealed that resveratrol alleviated cerebral I/R injury and reduced infarct size [161], which was consistent with another study [162]. For inhibition of excessive autophagy, several studies demonstrated that dexmedetomidine (DEX) was capable of rendering neuroprotection after ischemic stroke via inhibition of excessive autophagy. In the primary cultured neurons in oxygen-glucose deprivation (OGD) model and tMCAO model, DEX protected mouse brain from ischemia-reperfusion injury via inhibition of neuronal autophagy by upregulation of HIF-1α [52]. Moreover, DEX has been reported to reduce autophagy effect and improve learning and memory dysfunction in rodent MCAO model [163]. A recent study showed that regulation of miR-199 was a potential mechanism by which DEX inhibited autophagy and promoted neurological recovery after ischemic stroke [164]. Propofol administration reduced the infarct size and improves the outcome of acute ischemic stroke [165, 166]. Recent studies demonstrated that propofol protects against cerebral ischemia/reperfusion injury via inhibition of excessive autophagy through regulation of mTOR/S6K1 or long noncoding RNA SNHG14 [167, 168]. Melatonin, an endogenous hormone, was demonstrated to significantly alleviate cerebral infarction, brain edema, and neuronal apoptosis after ischemic stroke inhibited ER stress-induced excessive autophagy [169]. Recently, Gao et al. showed Icariside II, one of the main active ingredients of Epimedii (a traditional Chinese medicine), protecting...
neurons in OGD and rodent MCAO models via inhibiting excessive autophagy through interfering with the PKG/GSK-3β signaling pathway [51].

Although accumulating research has been shown that agents targeting the autophagy pathway have therapeutic potential for IS, there are several limitations need to be considered. Firstly, the possible side effects of the agents should be considered. Besides enhancing autophagy, mTORC1 inhibition blocks protein and nucleotide synthesis, inhibits cell proliferation, and inhibits metabolism [170]. Long-term rapamycin administration may cause immunosuppression, and glucose intolerance due to mTORC1 is acutely sensitive to rapamycin whereas mTORC2 chronically sensitive to rapamycin in vivo [171]. In addition, recent studies mainly focused on the effect of autophagy regulation on neuronal cell damage but less on cell growth and secretion in ischemic stroke. Finally, the outcome of treatment targeting autophagy is not only associated to the degree of autophagy, but also to the administration time of autophagy regulators and drug dose as well as the administration route.

7. Conclusions and Future Perspectives

As aforementioned above, accumulating evidence demonstrates that autophagy plays a critical role in the pathological process of ischemic stroke, which may provide a potential therapeutic target for ischemic stroke. However, there are many unanswered questions that should be carefully and critically addressed by future studies to translate autophagy-based stroke therapies to the clinic. Whether there are noncanonical pathways that initiate maladaptive autophagy which is detrimental to neuronal cell survival? Autophagy after ischemic stroke involves a variety of pathways, but by which mechanisms regulation the degree of autophagy? Excessive autophagy is characterized by accumulated autophagosomes, while the underlying molecular mechanisms are still unclear. How to manipulate cell-specific autophagy in a selective manner without activating unwanted cell death signaling pathways? Given that IS-induced autophagy has both beneficial and detrimental effects, exploring the most likely influencing factors such as optimal time point for autophagy manipulation should be considered. Finally, the last and most important point is that translation of this therapeutic strategy from the laboratory to the clinic should be accompanied by robust preclinical studies in appropriate cell culture and animal models.

Data Availability

The data and materials can be obtained by contacting the corresponding author.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Xiaocheng Lu, Jian Zhang, and Yu Ding contributed equally to this work.

References

[1] A. L. Berkowitz, M. K. Mittal, H. C. McLane et al., “Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke,” International Journal of Stroke, vol. 9, no. 3, pp. 349–355, 2014.
[2] U. Fischer, D. Anca, M. Arnold et al., “Quality of life in stroke survivors after local intra-arterial thrombolysis,” Cerebrovasc Dis., vol. 25, no. 5, pp. 438–444, 2008.
[3] California Acute Stroke Pilot Registry, “Prioritizing interventions to improve rates of thrombolysis for ischemic stroke,” Neurology., vol. 64, no. 4, pp. 654–659, 2005.
[4] C. De Duve, “The lysosome,” Scientific American, vol. 208, pp. 64–72, 1963.
[5] A. Di Meco, M. E. Curtis, E. Lauretti, and D. Pratico, “Autophagy dysfunction in Alzheimer’s disease: mechanistic insights and new therapeutic opportunities,” Biological Psychiatry, vol. 87, no. 9, pp. 797–807, 2020.
[6] M. Allaire, P. E. Rautou, P. Codogno, and S. Lotersztajn, “Autophagy in liver diseases: time for translation?,” Journal of Hepatology, vol. 70, no. 5, pp. 985–998, 2019.
[7] M. Abdellatif, S. Sedej, D. Carmona-Gutierrez, F. Madeo, and G. Kroemer, “Autophagy in cardiovascular aging,” Circulation Research, vol. 123, no. 7, pp. 803–824, 2018.
[8] J. Ren and Y. Zhang, “Targeting autophagy in aging and aging-related cardiovascular diseases,” Trends in Pharmacological Sciences, vol. 39, no. 12, pp. 1064–1076, 2018.
[9] X. Zhang, H. Yan, Y. Yuan et al., “Cerebral ischemia-reperfusion-induced autophagy protects against neuronal injury by mitochondrial clearance,” Autophagy, vol. 9, no. 9, pp. 1321–1333, 2013.
[10] S. Shaikh, K. Ahmad, S. S. Ahmad et al., “Natural products in therapeutic management of multineurodegenerative disorders by targeting autophagy,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 6347792, 12 pages, 2021.
[11] A. K. Verma, P. S. Bhatti, S. Rafat et al., “Autophagy paradox of cancer: role, regulation, and duality,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 8832541, 17 pages, 2021.
[12] Z. Zhang, X. Yang, Y. Q. Song, and J. Tu, “Autophagy in Alzheimer’s disease pathogenesis: therapeutic potential and future perspectives,” Ageing Research Reviews, vol. 72, article 101464, 2021.
[13] L. Tyutyunyuk-Massey and D. A. Gewirtz, “Roles of autophagy in breast cancer treatment: target, bystander or benefactor,” Seminars in Cancer Biology, vol. 66, pp. 155–162, 2020.
[14] M. E. Choi, “Autophagy in kidney disease,” Annual Review of Physiology, vol. 82, pp. 297–322, 2020.
[15] S. V. Retnakumar and S. Muller, “Pharmacological autophagy regulators as therapeutic agents for inflammatory bowel diseases,” Trends in Molecular Medicine, vol. 25, no. 6, pp. 516–537, 2019.
[16] N. Jimenez-Moreno and J. D. Lane, “Autophagy and redox homeostasis in Parkinson’s: a crucial balancing act,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 8865611, 38 pages, 2020.
[17] C. F. Bento, M. Renna, G. Ghislat et al., “Mammalian autophagy: how does it work?,” *Annual Review of Biochemistry*, vol. 85, pp. 685–713, 2016.

[18] D. J. Kast and R. Dominguez, “The cytoktosome-autophagy connection,” *Current Biology: CB*, vol. 27, no. 8, pp. R318–RR26, 2017.

[19] A. Kheminets, C. Behl, and I. Dikic, “Ubiquitin-dependent and independent signals in selective autophagy,” *Trends Cell Biology*, vol. 26, no. 1, pp. 6–16, 2016.

[20] S. Geiser, K. M. Holmström, D. Skujat et al., “PIN5K1/Parkin-mediated mitophagy is dependent on VDAC1 and p 62/SQSTM1,” *Nature Cell Biology*, vol. 12, no. 2, pp. 119–131, 2010.

[21] T. L. Thurston, G. Ryzhakov, S. Bloor, N. von Muhlinen, and F. Randow, “The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria,” *Nature Immunology*, vol. 10, no. 11, pp. 1215–1221, 2009.

[22] W. W. Li, J. Li, and J. K. Bao, “Microautophagy: lesser-known self-eating,” *Cellular and molecular life sciences: CMLS*, vol. 69, no. 7, pp. 1125–1136, 2012.

[23] A. V. Kalachev and O. V. Yurchenko, “Microautophagy in nutritive phagocytes of sea urchins,” *Protoplasma*, vol. 254, no. 1, pp. 609–614, 2017.

[24] A. Uttenweiler, H. Schwarz, and A. Mayer, “Microautophagic vacuole invagination requires calmodulin in a Ca2+-independent function,” *The Journal of Biological Chemistry*, vol. 280, no. 39, pp. 33289–33297, 2005.

[25] P. W. L. Ho, C. T. Leung, H. Liu et al., “Age-dependent accumulation of oligomeric SNCA/alpha-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA),” *Autophagy*, vol. 16, no. 2, pp. 347–370, 2020.

[26] J. Zhang, J. Huang, Y. Gu et al., “Inflammation-induced inhibition of chaperone-mediated autophagy maintains the immunosuppressive function of murine mesenchymal stromal cells,” *Cellular & molecular immunology.*, vol. 18, no. 6, pp. 1476–1488, 2020.

[27] S. Dash, Y. Aydin, and K. Moroz, “Chaperone-mediated autophagy in the liver: good or bad?,” *Cells*, vol. 8, no. 11, 2019.

[28] J. Kim, M. Kundu, B. Viiolet, and K. L. Guan, “AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk 1,” *Nature Cell Biology*, vol. 13, no. 2, pp. 132–141, 2011.

[29] T. J. Mercer, A. Gubas, and S. A. Tooze, “A molecular perspective of mammalian autophagosome biogenesis,” *The Journal of Biological Chemistry*, vol. 293, no. 15, pp. 5386–5395, 2018.

[30] L. Yu, C. K. McPhee, L. Zheng et al., “Termination of autophagy and reformation of lysosomes regulated by mTOR,” *Nature*, vol. 465, no. 7300, pp. 942–946, 2010.

[31] V. Kirkin, D. G. McEwan, I. Novak, and I. Dikic, “A role for ubiquitin in selective autophagy,” *Molecular Cell*, vol. 34, no. 3, pp. 259–269, 2009.

[32] Z. Yang and D. J. Klionsky, “Mammalian autophagy: core molecular machinery and signaling regulation,” *Current Opinion in Cell Biology*, vol. 22, no. 2, pp. 124–131, 2010.

[33] B. Gabryel, A. Kost, and D. Kasprowska, “Neuronal autophagy in cerebral ischemia—a potential target for neuroprotective strategies?,” *Pharmacological Reports*, vol. 64, no. 1, pp. 1–15, 2012.

[34] Y. Kabeya, N. Mizushima, T. Ueno et al., “LC3, a mammalian homologue of yeast Atg 8p, is localized in autophagosome membranes after processing,” *The EMBO Journal*, vol. 19, no. 21, pp. 5720–5728, 2000.

[35] T. Yorimitsu and D. J. Klionsky, “Autophagy: molecular machinery for self-eating,” *Cell Death and Differentiation*, vol. 12, Suppl 2, pp. 1542–1552, 2005.

[36] S. T. Shibutani, T. Saitoh, H. Nowag, C. Munz, and T. Yoshimori, “Autophagy and autophagy-related proteins in the immune system,” *Nature Immunology*, vol. 16, no. 10, pp. 1014–1024, 2015.

[37] H. Nakatogawa, Y. Ichimura, and Y. Ohsumi, “Atg 8, a ubiquitin-like protein required for autophagosome formation, mediates membrane tethering and hemifusion,” *Cell*, vol. 130, no. 1, pp. 165–178, 2007.

[38] N. Mizushima, “Autophagy: process and function,” *Genes & Development*, vol. 21, no. 22, pp. 2861–2873, 2007.

[39] T. C. Sudhof and J. E. Rothman, “Membrane fusion: grappling with SNARE and SM proteins,” *Science*, vol. 323, pp. 5913, pp. 474–477, 2009.

[40] F. Reggiori and C. Ungermann, “Autophagosome maturation and fusion,” *Journal of Molecular Biology*, vol. 429, no. 4, pp. 486–496, 2017.

[41] P. Jiang, N. Mizushima, Y. Sakamaki et al., “The HOPS complex mediates autophagosome-lysosome fusion through interaction with syntaxin 17,” *Molecular Biology of The Cell*, vol. 25, no. 8, pp. 1327–1337, 2014.

[42] M. Koike, M. Shibata, M. Tadakoshi et al., “Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury,” *The American Journal of Pathology*, vol. 172, no. 2, pp. 454–469, 2008.

[43] F. Xu, J. H. Gu, and Z. H. Qin, “Neuronal autophagy in cerebral ischemia,” *Neuroscience Bulletin*, vol. 28, no. 5, pp. 658–666, 2012.

[44] J. Puyal, A. Vaslin, V. Mottier, and P. G. Clarke, “Postischemic treatment of neonatal cerebral ischemia should target autophagy,” *Annals Of Neurology*, vol. 66, no. 3, pp. 378–389, 2009.

[45] C. Xie, V. Ginet, Y. Sun et al., “Neuroprotection by selective neuronal deletion of Atg 7 in neonatal brain injury,” *Autophagy*, vol. 12, no. 2, pp. 410–423, 2016.

[46] Q. Dai, S. Li, T. Liu et al., “Interleukin-17A-mediated alleviation of cortical astrocytic ischemic injuries affected the neurological outcome of mice with ischemic stroke,” *Journal of Cellular Biochemistry*, vol. 120, no. 7, pp. 11498–11509, 2019.

[47] Q. Zeng, J. Liu, P. Cao et al., “Inhibition of REDD1 sensitizes bladder urothelial carcinoma to paclitaxel by inhibiting autophagy,” *Clinical Cancer Research*, vol. 24, no. 2, pp. 445–459, 2018.

[48] J. Sun and F. Yue, “Suppression of REDD1 attenuates oxygen glucose deprivation/reoxygenation-evoked ischemic injury in neuron by suppressing mTOR-mediated excessive autophagy,” *Journal of Cellular Biochemistry*, vol. 120, no. 9, pp. 14771–14779, 2019.

[49] D. M. Zhang, T. Zhang, M. M. Wang et al., “TIGAR alleviates ischemia/reperfusion-induced autophagy and ischemic brain injury,” *Free Radical Biology & Medicine*, vol. 137, pp. 13–23, 2019.

[50] G. Wang, T. Wang, Y. Zhang, F. Li, B. Yu, and J. Kou, “Schizandrin protects against OGD/R-induced neuronal injury by suppressing autophagy: involvement of the AMPK/mTOR pathway,” *Molecules*, vol. 24, no. 19, article 3624, 2019.
Oxidative Medicine and Cellular Longevity

[51] J. Gao, L. Long, F. Xu et al., “Icariside II, a phosphodiesterase 5 inhibitor, attenuates cerebral ischaemia/reperfusion injury by inhibiting glycogen synthase kinase-3beta-mediated activation of autophagy,” British Journal of Pharmacology, vol. 177, no. 6, pp. 1434–1452, 2020.

[52] C. Luo, M. W. Ouyang, Y. Y. Fang et al., “Dexmedetomidine protects mouse brain from ischemia-reperfusion injury via inhibiting neuronal autophagy through up-regulating HIF-1alpha,” Frontiers in Cellular Neuroscience, vol. 11, article 197, 2017.

[53] J. Zhang and J. F. He, “Lnc RNA-MALAT1 influences myocardial infarction by regulating mi R-30a/30c-1 pathway,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 2, pp. 885–892, 2020.

[54] J. L. Chen, X. X. Wang, L. Chen et al., “A sphingosine kinase 2-mimicking TAT-peptide protects neurons against ischemia-reperfusion injury by activating Bnip3-mediated mitophagy,” Neuropharmacology, vol. 181, article 108326, 2020.

[55] Z. Lai, L. Gu, L. Yu et al., “Delta opioid peptide [d-Ala 2, d-Leu 5] enkephalin confers neuroprotection by activating delta opioid receptor-AMPK-autophagy axis against global ischemia,” Cell & bioscience, vol. 10, pp. 1–18, 2020.

[56] K. Wei, P. Wang, and C. Y. Miao, “A double-edged sword with therapeutic potential: an updated role of autophagy in ischemic cerebral injury,” CNS Neuroscience & Therapeutics, vol. 18, no. 11, pp. 879–886, 2012.

[57] W. Xu, P. Xiao, S. Fan et al., “Blockade of Nogo-A/Nogo-66 receptor 1 (NgR1) inhibits autophagic activation and prevents secondary neuronal damage in the thalamus after focal cerebral infarction in hypertensive rats,” Neuroscience, vol. 431, pp. 103–114, 2020.

[58] Y. Yang, H. Gao, W. Liu et al., “Arctic lappa L. roots ameliorates cerebral ischemia through inhibiting neuronal apoptosis and suppressing AMPK/mTOR-mediated autophagy,” Phytomedicine, vol. 85, article 153526, 2021.

[59] C. Chen, Q. Yu, K. Xu et al., “Electroacupuncture pretreatment prevents ischemic stroke and inhibits Wnt signaling-mediated autophagy through the regulation of GSK-3beta phosphorylation,” Brain Research Bulletin, vol. 158, pp. 90–98, 2020.

[60] H. C. Luo, T. Z. Yi, F. G. Huang, Y. Wei, X. P. Luo, and Q. S. Luo, “Role of long noncoding RNA MEG3/mi R-378/GRB2 axis in neuronal autophagy and neurofunctional impairment in ischemic stroke,” The Journal of Biological Chemistry, vol. 295, no. 41, pp. 14125–14139, 2020.

[61] H. Li, J. Shang, C. Zhang, R. Lu, J. Chen, and X. Zhou, “Repetitive transcranial magnetic stimulation alleviates neurological deficits after cerebral ischemia through interaction between RACK1 and BDNF exon IV by the phosphorylation-dependent factor MeCP2,” Neurotherapeutics, vol. 17, no. 2, pp. 651–666, 2020.

[62] P. Wang, Y. F. Guan, H. Du, Q. W. Zhai, D. F. Su, and C. Y. Miao, “Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia,” Autophagy, vol. 8, no. 1, pp. 77–87, 2012.

[63] S. Carloni, G. Buonocore, and W. Balduini, “Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury,” Neurobiology of Disease, vol. 32, no. 3, pp. 329–339, 2008.

[64] S. Carloni, S. Girelli, C. Scopa, G. Buonocore, M. Longini, and W. Balduini, “Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia,” Autophagy, vol. 6, no. 3, pp. 366–377, 2010.

[65] K. M. Buckley, D. L. Hess, I. Y. Sazonova et al., “Rapamycin up-regulation of autophagy reduces infarct size and improves outcomes in both permanent MCAO, and embolic MCAO, murine models of stroke,” Experimental & Translational Stroke Medicine, vol. 6, pp. 1–9, 2014.

[66] X. Yang, C. Hei, P. Liu et al., “Inhibition of mTOR pathway by rapamycin reduces brain damage in rats subjected to transient forebrain ischemia,” International Journal of Biological Sciences, vol. 11, no. 12, pp. 1424–1435, 2015.

[67] X. Liu, F. Tian, S. Wang, F. Wang, and L. Xiong, “Astrocyte autophagy flux protects neurons against oxygen-glucose deprivation and ischemic/reperfusion Injury,” Rejuvenation Research, vol. 21, no. 5, pp. 405–415, 2018.

[68] G. Hadley, D. J. Beard, Y. Couch et al., “Rapamycin in ischemic stroke: old drug, new tricks?,” Journal of Cerebral Blood Flow & Metabolism, vol. 39, no. 1, pp. 20–35, 2019.

[69] D. D. Song, T. T. Zhang, J. L. Chen et al., “Sphingosine kinase 2 activates autophagy and protects neurons against ischemic injury through interaction with Bcl-2 via its putative BH3 domain,” Cell Death & Disease, vol. 8, no. 7, article e2912, 2017.

[70] J. Yu, X. Li, N. Matei et al., “Eezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK dependent autophagy activation after MCAO in rats,” Experimental Neurology, vol. 307, pp. 12–23, 2018.

[71] X. Chen, S. Lin, L. Gu et al., “Inhibition of mi R-497 improves functional outcome after ischemic stroke by enhancing neuronal autophagy in young and aged rats,” Neurochemistry International, vol. 127, pp. 64–72, 2019.

[72] L. Y. Ao, W. T. Li, L. Zhou et al., “Therapeutic effects of JLX-001 on ischemic stroke by inducing autophagy via AMPK-ULK1 signaling pathway in rats,” Brain Research Bulletin, vol. 153, pp. 162–170, 2019.

[73] R. Cao, L. Li, Z. Ying et al., “A small molecule protects mitochondrial integrity by inhibiting mTOR activity,” Proceedings of the National Academy of Sciences, vol. 116, no. 46, pp. 23332–23338, 2019.

[74] Y. J. Yuan, Z. Ye, H. Yu et al., “Shrm 4 contributes to autophagy inhibition and neuroprotection following ischemic stroke by mediating GABAB receptor activation,” The FASEB Journal, vol. 34, no. 12, pp. 15837–15848, 2020.

[75] M. Ghosh, Y. Xu, and D. D. Pearse, “Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines,” Journal of Neuroinflammation, vol. 13, article 9, 2016.

[76] K. Jackman and C. Iadecola, “Neurovascular regulation in the ischemic brain,” Antioxidants & Redox Signaling, vol. 22, no. 2, pp. 149–160, 2015.

[77] K. A. Kigerl, J. C. Gensel, D. P. Ankeny, I. K. Alexander, D. J. Donnelly, and P. G. Popovich, “Identification of two distinct macrophage subsets with divergent effects triggering either neurotoxicity or regeneration in the injured mouse spinal cord,” Journal of Neuroscience, vol. 29, no. 43, pp. 13435–13444, 2009.

[78] F. Y. McWhorter, T. Wang, P. Nguyen, T. Chung, and W. F. Liu, “Modulation of macrophage phenotype by cell shape,” Proceedings of the National Academy of Sciences, vol. 110, no. 43, pp. 17253–17258, 2013.

[79] K. Sajio and C. K. Glass, “Microglial cell origin and phenotypes in health and disease,” Nature Reviews Immunology, vol. 11, no. 11, pp. 775–787, 2011.
[80] S. Y. Cheon, E. J. Kim, J. M. Kim, E. H. Kam, B. W. Ko, and B. N. Koo, “Regulation of microglia and macrophage polarization via apoptosis signal-regulating kinase 1 silencing after ischemic/hypoxic injury,” *Frontiers in Molecular Neuroscience*, vol. 10, article 261, 2017.

[81] S. Hamzei Taj, D. Le Blon, C. Hoornaert et al., “Targeted intracerebral delivery of the anti-inflammatory cytokine IL13 promotes alternative activation of both microglia and macrophages after stroke,” *Journal of Neuroinflammation*, vol. 15, pp. 1–17, 2018.

[82] C. Porta, M. Rimoldi, G. Raes et al., “Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappa B,” *Proceedings of the National Academy of Sciences*, vol. 106, no. 35, pp. 14978–14983, 2009.

[83] J. Ni, Z. Wu, C. Peteris, K. Yamamoto, H. Qing, and H. Nakanishi, “The critical role of proteolytic relay through cathepsins B and E in the phenotypic change of microglia/macrophage,” *The Journal of Neuroscience*, vol. 35, no. 36, pp. 12488–12501, 2015.

[84] Z. Yang, L. Zhong, S. Zhong, R. Xian, and B. Yuan, “Hypoxia induces microglia autophagy and neural inflammation injury in focal cerebral ischemia model,” *Experimental and Molecular Pathology*, vol. 98, no. 2, pp. 219–224, 2015.

[85] S. Yang, H. Wang, Y. Yang et al., “Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage,” *Biomedicine & Pharmacotherapy*, vol. 117, article 109102, 2019.

[86] H. Y. He, L. Ren, T. Guo, and Y. H. Deng, “Neuronal autophagy aggravates microglial inflammatory injury by downregulating CX3CL1/fractalkine after ischemic stroke,” *Neural Regeneration Research*, vol. 14, no. 2, pp. 280–288, 2019.

[87] Y. Zhu, J. Yu, J. Gong et al., “PTP1B inhibitor alleviates deleterious microglial activation and neuronal injury after ischemic stroke by modulating the ER stress-autophagy axis via PERK signaling in microglia,” *Aging (Albany NY)*, vol. 13, no. 3, pp. 3405–3427, 2021.

[88] H. Wang, Q. Liu, and X. Zhang, “C1q/tumor necrosis factor-related protein-1 attenuates microglia autophagy and inflammatory response by regulating the Akt/mTOR pathway,” *Life sciences*, vol. 256, article 117992, 2020.

[89] L. Wang, X. Xiong, X. Zhang et al., “Sodium tanshinone IIA sulfonate protects against cerebral ischemia-reperfusion injury by inhibiting autophagy and inflammation,” *Neuroscience*, vol. 441, pp. 46–57, 2020.

[90] B. Han, W. Jiang, P. Cui et al., “Microglial PGC-1alpha protects against ischemic brain injury by suppressing neuroinflammation,” *Genome Medicine*, vol. 13 1, pp. 1–19, 2021.

[91] C. Y. Xia, S. Zhang, S. F. Chu et al., “Autophagic flux regulates microglial phenotype according to the time of oxygen-glucose deprivation/reperfusion,” *International Immunopharmacology*, vol. 39, pp. 140–148, 2016.

[92] C. Fu, X. Zhang, Y. Lu et al., “Geniposide inhibits NLRP3 inflammasome activation via autophagy in BV-2 microglial cells exposed to oxygen-glucose deprivation/reoxygenation,” *International Immunopharmacology*, vol. 84, article 106547, 2020.

[93] C. Espinosa-Garcia, F. Atif, S. Yousuf, I. Sayeed, G. N. Neigh, and D. G. Stein, “Progesterone attenuates stress-induced NLRP3 inflammasome activation and enhances autophagy following ischemic brain injury,” *International Journal of Molecular Sciences*, vol. 21, no. 11, article 3740, 2020.

[94] Z. Liu and M. Chopp, “Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke,” *Progress in Neurobiology*, vol. 144, pp. 103–120, 2016.

[95] M. Li, Z. Li, Y. Yao et al., “Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity,” *Proceedings of the National Academy of Sciences*, vol. 114, no. 3, pp. E396–E405, 2017.

[96] Y. F. Dong, Z. Z. Chen, Z. Zhao et al., “Potential role of micro RNA-7 in the anti-neuroinflammation effects of nicorandil in astrocytes induced by oxygen-glucose deprivation,” *Journal of Neuroinflammation*, vol. 13, no. 1, pp. 1–10, 2016.

[97] H. Liu, X. Wu, J. Luo et al., “Pterostilbene attenuates astrocytic inflammation and neuronal oxidative injury after ischemia-reperfusion by inhibiting NF-kappa B phosphorylation,” *Frontiers in Immunology*, vol. 10, article 2408, 2019.

[98] X. Wu, J. Luo, H. Liu et al., “Recombinant adiponectin peptide ameliorates brain injury following intracerebral hemorrhage by suppressing astrocyte-derived inflammation via the inhibition of Drp 1-mediated mitochondrial fission,” *Translational Stroke Research*, vol. 11, no. 5, pp. 924–939, 2020.

[99] E. Cekanaviute and M. S. Buckwalter, “Astrocytes: integrative regulators of neuroinflammation in stroke and other neurologic diseases,” *Neurotherapeutics*, vol. 13, no. 4, pp. 685–701, 2016.

[100] S. T. Carmichael, “Cellular and molecular mechanisms of neural repair after stroke: making waves,” *Annals of Neurology*, vol. 59, no. 5, pp. 735–742, 2006.

[101] Z. Liu, Y. Li, Y. Cui et al., “Beneficial effects of galf/vimentin reactive astrocytes for axonal remodeling and motor behavioral recovery in mice after stroke,” *Glia*, vol. 62, no. 12, pp. 2022–2033, 2014.

[102] Z. G. Zhang and M. Chopp, “Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic,” *Lancet Neurology*, vol. 8, no. 5, pp. 491–500, 2009.

[103] A. P. Qin, C. F. Liu, Y. Y. Qin et al., “Autophagy was activated in injured astrocytes and mildly decreased cell survival following glucose and oxygen deprivation and focal cerebral ischemia,” *Autophagy*, vol. 6, no. 6, pp. 738–753, 2010.

[104] X. Y. Zhou, Y. Luo, Y. M. Zhu et al., “Inhibition of autophagy blocks cathepsins-tBid-mitochondrial apoptotic signaling pathway via stabilization of lysosomal membrane in ischemic astrocytes,” *Cell Death & Disease*, vol. 8, no. 2, article e2618, 2017.

[105] Y. Ni, W. W. Gu, Z. H. Liu et al., “RIP1K contributes to neuronal and astrocytic cell death in ischemic stroke via activating autophagic-lysosomal pathway,” *Neuroscience*, vol. 371, pp. 60–74, 2018.

[106] B. Han, Y. Zhang, Y. Zhang et al., “Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke,” *Autophagy*, vol. 14, no. 7, pp. 1164–1184, 2018.

[107] D. Zhou, Z. Huang, X. Zhu, T. Hong, and Y. Zhao, “Circular RNA 0025984 ameliorates ischemic stroke injury and protects astrocytes through mi R-143-3p/TET1/ORP150 pathway,” *Molecular Neurobiology*, vol. 58, no. 11, pp. 5937–5953, 2021.

[108] C. Zhu, Q. Zhou, C. Luo, and Y. Chen, “Dexametomidine protects against oxygen-glucose deprivation-induced injury through inducing astrocytes autophagy via TSC2/mTOR pathway,” *Neuromolecular Medicine*, vol. 22, no. 2, pp. 210–217, 2020.
[109] X. S. Wang, J. Yue, L. N. Hu et al., “Activation of G protein-coupled receptor 30 protects neurons by regulating autophagy in astrocytes,” Glia, vol. 68, no. 1, pp. 27–43, 2020.

[110] Y. Zhang and J. M. Miao, “Ginkgolide K promotes astrocyte proliferation and migration after oxygen-glucose deprivation via inducing protective autophagy through the AMPK/mTOR/ULK1 signaling pathway,” European Journal of Pharmacology, vol. 832, pp. 96–103, 2018.

[111] S. A. Back, B. H. Han, N. L. Luo et al., “Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia,” Journal of Neuroscience, vol. 22, no. 2, pp. 455–463, 2002.

[112] D. Dewar, S. M. Underhill, and M. P. Goldberg, “Oligodendrocytes and ischemic brain injury,” Journal of Cerebral Blood Flow and Metabolism, vol. 23, no. 3, pp. 263–274, 2003.

[113] C. Matute, M. Domercq, A. Perez-Samartin, and B. R. Ransom, “Protecting white matter from stroke injury,” Stroke; a Journal of Cerebral Circulation, vol. 44, no. 4, pp. 1204–1211, 2013.

[114] Y. Ma, J. Wang, Y. Wang, and G. Y. Yang, “The biphasic function of microglia in ischemic stroke,” Progress in Neurobiology, vol. 157, pp. 247–272, 2017.

[115] L. Zhang, L. Y. Dong, Y. J. Li, Z. Hong, and W. S. Wei, “mi R-21 represses Fas L in microglia and protects against microglia-mediated neuronal cell death following hypoxia/ischemia,” Glia, vol. 60, no. 12, pp. 1888–1895, 2012.

[116] L. Li, K. M. Harms, P. B. Ventura, D. C. Lagace, A. J. Eisch, and L. A. Cunningham, “Focal cerebral ischemia induces a multilineage cytogenic response from adult subventricular zone that is predominantly gliogenic,” Glia, vol. 58, no. 13, pp. 1610–1619, 2010.

[117] A. N. Bankston, M. D. Forston, R. M. Howard et al., “Autophagy is essential for oligodendrocyte differentiation, survival, and proper myelination,” Glia, vol. 67, no. 9, pp. 1745–1759, 2019.

[118] S. S. Ohri, A. N. Bankston, S. A. Mullins et al., “Blocking autophagy in oligodendrocytes limits functional recovery after spinal cord injury,” Journal of Neuroscience, vol. 38, no. 26, pp. 5900–5912, 2018.

[119] L. Strohm and C. Behrends, “Glia-specific autophagy dysfunction in ALS,” Seminars in Cell & Developmental Biology, vol. 99, pp. 172–182, 2020.

[120] S. Kaji, T. Maki, H. Kinoshita et al., “Pathological endogenous alpha-synuclein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system atrophy,” Stem Cell Reports, vol. 10, no. 2, pp. 356–365, 2018.

[121] C. W. Keller and J. D. Lunemann, “Noncanonical autophagy in dendritic cells triggers CNS autoimmunity,” Autophagy, vol. 14, no. 3, pp. 560–561, 2018.

[122] S. Seo, H. Kim, J. H. Sung, N. Choi, K. Lee, and H. N. Kim, “Microphysiological systems for recapitulating physiology and function of blood-brain barrier,” Biomaterials, vol. 232, article 119732, 2020.

[123] U. H. Langen, S. Aylooo, and C. Gu, “Development and cell biology of the blood-brain barrier,” Annual Review of Cell and Developmental Biology, vol. 35, pp. 591–613, 2019.

[124] Y. Yang, E. Y. Estrada, J. F. Thompson, W. Liu, and G. A. Rosenberg, “Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 4, pp. 697–709, 2007.

[125] J. Liu, X. Jin, K. J. Liu, and W. Liu, “Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage,” Journal of Neuroscience, vol. 32, no. 9, pp. 3044–3057, 2012.

[126] L. Fang, X. Li, Y. Zhong et al., “Autophagy protects human brain microvascular endothelial cells against methylglyoxal-induced injuries, reproducible in a cerebral ischemic model in diabetic rats,” Journal of Neurochemistry, vol. 135, no. 2, pp. 431–440, 2015.

[127] H. Li, A. Gao, D. Feng et al., “Evaluation of the protective potential of brain microvascular endothelial cell autophagy on blood-brain barrier integrity during experimental cerebral ischemia-reperfusion injury,” Translational Stroke Research, vol. 5, no. 5, pp. 618–626, 2014.

[128] T. Urbanek, W. Kuczmiak, A. Basta-Kaim, and B. Gabryel, “Rapamycin induces protective autophagy in vascular endothelial cells exposed to oxygen-glucose deprivation,” Brain Research, vol. 1553, pp. 1–11, 2014.

[129] J. Yu, C. Li, Q. Ding et al., “Netrin-1 ameliorates blood-brain barrier impairment secondary to ischemic stroke via the activation of PI3K pathway,” Frontiers in Neuroscience, vol. 11, article 700, 2017.

[130] Z. Yang, C. Huang, X. Wen et al., “Circular RNA circ-Fox O3 attenuates blood-brain barrier damage by inducing autophagy during ischemia/reperfusion,” Molecular Therapy, vol. 30, no. 3, pp. 1275–1287, 2021.

[131] Z. Li, J. Li, and N. Tang, “Long noncoding RNA Malat 1 is a potent autophagy inducer protecting brain microvascular endothelial cells against oxygen-glucose deprivation/reoxygenation-induced injury by sponging mi R-26b and upregulating ULK2 expression,” Neuroscience, vol. 354, pp. 1–10, 2017.

[132] W. L. Li, S. P. Yu, D. Chen et al., “The regulatory role of NF-kappa B in autophagy-like cell death after focal cerebral ischemia in mice,” Neurobiology, vol. 244, pp. 16–30, 2013.

[133] S. Zhang, Q. An, T. Wang, S. Gao, and G. Zhou, “Autophagy and MMP-2/9-mediated reduction and redistribution of ZO-1 contribute to hyperglycemia-increased blood-brain barrier permeability during early reperfusion in stroke,” Neuroscience, vol. 377, pp. 126–137, 2018.

[134] N. Wei, S. P. Yu, X. H. Gu et al., “The involvement of autophagy pathway in exaggerated ischemic brain damage in diabetic mice,” CNS Neuroscience & Therapeutics, vol. 19, no. 10, pp. 753–763, 2013.

[135] J. Liu, J. Weaver, X. Jin et al., “Nitric oxide interacts with caveolin-1 to facilitate autophagy-lysosome-mediated claudin-5 degradation in oxygen-glucose deprivation-treated endothelial cells,” Molecular Neurobiology, vol. 53, no. 9, pp. 5935–5947, 2016.

[136] Y. Zhang, X. Zhang, Q. Wei et al., “Activation of sigma-1 receptor enhanced pericyte survival via the interplay between apoptosis and autophagy: implications for blood-brain barrier integrity in stroke,” Translational Stroke Research, vol. 11, no. 2, pp. 267–287, 2020.

[137] Y. Yin, G. Sun, E. Li, K. Kiselyov, and D. Sun, “ER stress and impaired autophagy flux in neuronal degeneration and brain injury,” Ageing Research Reviews, vol. 34, pp. 3–14, 2017.

[138] Z. Zhang, J. Shi, E. C. Nice, C. Huang, and Z. Shi, “The multifaceted role of flavonoids in cancer therapy: leveraging autophagy with a double-edged sword,” Antioxidants, vol. 10, no. 7, 2021.
[139] S. Wang, K. Zhang, Y. Yao, and J. Li, “Autophagy and mitochondrial homeostasis during infection: a double-edged sword,” Frontiers in Cell and Developmental Biology, vol. 9, article 738932, 2021.

[140] C. Kang and L. Avery, “To be or not to be, the level of autophagy is the question: dual roles of autophagy in the survival response to starvation,” Autophagy, vol. 4, no. 1, pp. 82–84, 2008.

[141] R. Shi, J. Weng, L. Zhao, X. M. Li, T. M. Gao, and J. Kong, “Excessive autophagy contributes to neuron death in cerebral ischemia,” CNS Neuroscience & Therapeutics, vol. 18, no. 3, pp. 250–260, 2012.

[142] W. Yan, H. Zhang, X. Bai, Y. Lu, H. Dong, and L. Xiong, “Autophagy activation is involved in neuroprotection induced by hyperbaric oxygen preconditioning against focal cerebral ischemia in rats,” Brain Research, vol. 1402, pp. 109–121, 2011.

[143] L. Gao, T. Jiang, J. Guo et al., “Inhibition of autophagy contributes to ischemic postconditioning-induced neuroprotection against focal cerebral ischemia in rats,” PloS One, vol. 7, no. 9, article e46092, 2012.

[144] Z. F. Qi, Y. M. Luo, X. R. Liu et al., “AKT/GSK3beta-dependent autophagy contributes to the neuroprotection of limb remote ischemic postconditioning in the transient cerebral ischemic rat model,” CNS Neuroscience & Therapeutics, vol. 18, no. 12, pp. 965–973, 2012.

[145] Z. Qi, W. Dong, W. Shi et al., “Bcl-2 phosphorylation triggers autophagy switch and reduces mitochondrial damage in limb remote ischemic conditioned rats after ischemic stroke,” Translational Stroke Research, vol. 6, no. 3, pp. 198–206, 2015.

[146] J. M. Henderson, C. Weber, and D. Santovito, “Beyond self-recycling: cell-specific role of autophagy in atherosclerosis,” Cells, vol. 10, no. 3, article 625, 2021.

[147] A. N. Patrizzi, J. F. Moruno-Manchon, L. M. O’Keefe et al., “Sex-specific differences in autophagic responses to experimental ischemic stroke,” Cells, vol. 10, no. 7, article 1825, 2021.

[148] W. J. Zhong, X. S. Yang, H. Zhou, B. R. Xie, W. W. Liu, and Y. Li, “Role of mitophagy in the pathogenesis of stroke: from mechanism to therapy,” Oxidative Medicine and Cellular Longevity, vol. 2022, Article ID 6232902, 13 pages, 2022.

[149] W. Xu, U. Ocak, L. Gao et al., “Selective autophagy as a therapeutic target for neurodegenerative diseases,” Cellular and Molecular Life Sciences: CMLS, vol. 78, no. 4, pp. 1369–1392, 2021.

[150] Y. Zhao, X. Shi, J. Wang, J. Mang, and Z. Xu, “Betulonic acid ameliorates cerebral injury in middle cerebral artery occlusion rats through regulating autophagy,” ACS Chemical Neuroscience, vol. 12, no. 15, pp. 2829–2837, 2021.

[151] X. Guo, W. Wang, D. Zheng, X. Cheng, and Y. Sun, “Lnc RNA-MIAT promotes neural cell autophagy and apoptosis in ischemic stroke by up-regulating REDD1,” Brain research., vol. 1765, article 147436, 2021.

[152] N. Liu, A. Peng, H. Sun et al., “Lnc RNA AC136007.2 alleviates cerebral ischemic-reperfusion injury by suppressing autophagy,” Aging (Albany NY), vol. 13, no. 15, pp. 19587–19597, 2021.

[153] J. Zhao, Y. Dong, X. Chen et al., “p53 inhibition protects against neuronal ischemia/reperfusion injury by the p53/PRAS40/mTOR pathway,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 4729465, 18 pages, 2021.

[154] Z. Yang, X. Shi, Z. Gao, and L. Chu, “miR-155-5p in extracellular vesicles derived from choroid plexus epithelial cells promotes autophagy and inflammation to aggravate ischemic brain injury in mice,” Oxidative Medicine and Cellular Longevity, vol. 2022, Article ID 8603427, 21 pages, 2022.

[155] J. Wang, X. Lin, Z. Mu et al., “Rapamycin increases collateral circulation in rodent brain after focal ischemia as detected by multiple modality dynamic imaging,” Theranostics, vol. 9, no. 17, pp. 4923–4934, 2019.

[156] D. J. Beard, G. Hadley, N. Thurley, D. W. Howells, B. A. Sutherland, and A. M. Buchan, “The effect of rapamycin treatment on cerebral ischemia: a systematic review and meta-analysis of animal model studies,” International Journal of Stroke, vol. 14, no. 2, pp. 137–145, 2019.

[157] O. Z. Chi, S. J. Mellender, S. Barsoum, X. Liu, S. Damito, and H. R. Weiss, “Effects of rapamycin pretreatment on blood-brain barrier disruption in cerebral ischemia-reperfusion,” Neuroscience Letters, vol. 620, pp. 132–136, 2016.

[158] L. Li and J. Huang, “Rapamycin pretreatment alleviates cerebral ischemia/reperfusion injury in dose-response manner through inhibition of the autophagy and NFκB pathways in rats,” Dose-Response, vol. 18, no. 3, article 1559325820946194, 2020.

[159] M. Wu, H. Zhang, J. Kai et al., “Rapamycin prevents cerebral stroke by modulating apoptosis and autophagy in penumbra in rats,” Annals of Clinical and Translational Neurology, vol. 5, no. 2, pp. 138–146, 2018.

[160] J. Chen, Q. Bai, Z. Zhao, H. Sui, and X. Xie, “Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs,” Acta Neurologica Scandinavica, vol. 134, no. 1, pp. 54–60, 2016.

[161] Q. He, Z. Li, Y. Wang, Y. Hou, L. Li, and J. Zhao, “Resveratrol alleviates cerebral ischemia/reperfusion injury in rats by inhibiting NLRP3 inflammasome activation through Sirt1-dependent autophagy induction,” International Immunopharmacology, vol. 50, pp. 208–215, 2017.

[162] Y. Liu, H. Yang, G. Jia et al., “The synergistic neuroprotective effects of combined rosuvastatin and resveratrol pretreatment against cerebral ischemia/reperfusion injury,” Journal of Stroke and Cerebrovascular Diseases, vol. 27, no. 6, pp. 1697–1704, 2018.

[163] Y. Zhu, S. Li, J. Liu et al., “Role of JNK signaling pathway in dexametomidine post-conditioning-induced reduction of the inflammatory response and autophagy effect of focal cerebral ischemia reperfusion injury in rats,” Inflammation, vol. 42, no. 6, pp. 2181–2191, 2019.

[164] Y. Zhu, H. Zhao, W. Zhang, X. Ma, and Y. Liu, “Dexametomidine attenuates neuronal injury induced by cerebral ischemia-reperfusion injury in rats,” Molecular Medicine Reports, vol. 24, no. 2, pp. 1–10, 2021.

[165] A. W. Gelb, N. A. Bayona, J. X. Wilson, and D. F. Cechetto, “Propofol anesthesia compared to awake reduces infarct size in rats,” Anesthesiology, vol. 96, no. 5, pp. 1183–1190, 2002.

[166] B. Sun, H. Ou, F. Ren et al., “Propofol inhibited autophagy through Ca (2+)/CaMKKbeta/AMPK/mTOR pathway in OGD/R-induced neuron injury,” Molecular Medicine, vol. 24, pp. 1–11, 2018.

[167] Y. Wang, D. Tian, C. Wei et al., “Propofol attenuates alpha-synuclein aggregation and neuronal damage in a mouse model of ischemic stroke,” Neuroscience Bulletin, vol. 36, no. 3, pp. 289–298, 2020.
[168] B. Sun, H. Ou, F. Ren, Y. Guan, Y. Huan, and H. Cai, “Propofol protects against cerebral ischemia/reperfusion injury by down-regulating long noncoding RNA SNHG14,” ACS Chemical Neuroscience, vol. 12, no. 16, pp. 3002–3014, 2021.

[169] D. Feng, B. Wang, L. Wang et al., “Pre-ischemia melatonin treatment alleviated acute neuronal injury after ischemic stroke by inhibiting endoplasmic reticulum stress-dependent autophagy via PERK and IRE1 signalings,” Journal Of Pineal Research, vol. 62, no. 3, article e12395, 2017.

[170] R. A. Saxton and D. M. Sabatini, “mTOR signaling in growth, metabolism, and disease,” Cell, vol. 169, no. 2, pp. 361–371, 2017.

[171] S. I. Arriola Apelo and D. W. Lamming, “Rapamycin: an Inhibitor of aging emerges from the soil of Easter Island,” Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, vol. 71, no. 7, pp. 841–849, 2016.